BlackRock Health Sciences Trust
Sponsor: BlackRock · Inception Mar 29, 2005 · Pays monthly
Market priceShare price
$44.72
+1.53% (+$0.67)
NAVAsset value per share
$46.02
as of Oct 14, 2026 · Nasdaq NAV symbol
Premium / discountPrice vs. assets
2.82% discount *
Indicative: latest price vs latest reported NAV
Distribution rate (price)Payout rate
7.03%
regular, annualised · on NAV 6.83%
Expense ratioAnnual cost
Not reported
no tagged fee table
LeverageBorrowing
Not reported
senior securities not tagged
Quote status: Market closed — last regular-session price · last trade Oct 15, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 15, 2026, 10:43 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 25, 2026. 152 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | Equity | United States | 7.79% | $44.6M |
| 2 | UnitedHealth Group Inc | Equity | United States | 6.11% | $35M |
| 3 | Merck & Co Inc | Equity | United States | 5.22% | $29.9M |
| 4 | AbbVie Inc | Equity | United States | 5.06% | $29M |
| 5 | Gilead Sciences Inc | Equity | United States | 3.68% | $21.1M |
| 6 | Amgen Inc | Equity | United States | 3.37% | $19.3M |
| 7 | BlackRock Liquidity Funds | Short-term inv. | United States | 3.33% | $19M |
| 8 | Thermo Fisher Scientific Inc | Equity | United States | 2.96% | $17M |
| 9 | Vertex Pharmaceuticals Inc | Equity | United States | 2.77% | $15.9M |
| 10 | Edwards Lifesciences Corp | Equity | United States | 2.37% | $13.6M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Equity (common) | 96.27% | $551M |
| Short-term investment vehicle | 3.66% | $20.9M |
| Equity (preferred) | 0.07% | $389K |
| OTHER | 0.01% | $50.4K |
| Derivative (equity) | 0.00% | $0 |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| United States | 94.03% | $538M |
| Switzerland | 1.32% | $7.6M |
| Netherlands | 1.31% | $7.5M |
| Israel | 1.16% | $6.6M |
| United Kingdom | 0.86% | $4.9M |
| Bermuda | 0.34% | $1.9M |
| Belgium | 0.25% | $1.4M |
| Japan | 0.17% | $978K |
| Canada | 0.16% | $932K |
| Jersey | 0.13% | $757K |
| British Virgin Islands | 0.08% | $453K |
| Germany | 0.06% | $344K |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 94.03% | $538M |
| Developed Europe | 3.99% | $22.8M |
| Middle East | 1.16% | $6.6M |
| Offshore domiciles | 0.47% | $2.7M |
| Japan | 0.17% | $978K |
| Canada | 0.16% | $932K |
| Asia ex-Japan | 0.03% | $175K |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 96.56% | $553M |
| Registered fund | 3.44% | $19.7M |
| Other | 0.00% | $0 |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 1 | 97.32% | $557M |
| Level 2 | 2.03% | $11.6M |
| Level 3 | 0.65% | $3.7M |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 100.00% | $573M |
| N/A | 0.00% | $0 |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 152 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 478160104 | Equity | CORP | United States | 175,604 | shares | $44.6M | 7.79% | 1 |
| UnitedHealth Group Inc | 91324P102 | Equity | CORP | United States | 84,166 | shares | $35M | 6.11% | 1 |
| Merck & Co Inc | 58933Y105 | Equity | CORP | United States | 232,628 | shares | $29.9M | 5.22% | 1 |
| AbbVie Inc | 00287Y109 | Equity | CORP | United States | 115,083 | shares | $29M | 5.06% | 1 |
| Gilead Sciences Inc | 375558103 | Equity | CORP | United States | 166,662 | shares | $21.1M | 3.68% | 1 |
| Amgen Inc | 031162100 | Equity | CORP | United States | 53,219 | shares | $19.3M | 3.37% | 1 |
| BlackRock Liquidity Funds | 09248U718 | Short-term inv. | RF | United States | 19,047,042 | shares | $19M | 3.33% | 1 |
| Thermo Fisher Scientific Inc | 883556102 | Equity | CORP | United States | 33,830 | shares | $17M | 2.96% | 1 |
| Vertex Pharmaceuticals Inc | 92532F100 | Equity | CORP | United States | 31,983 | shares | $15.9M | 2.77% | 1 |
| Edwards Lifesciences Corp | 28176E108 | Equity | CORP | United States | 149,905 | shares | $13.6M | 2.37% | 1 |
| Eli Lilly & Co | 532457108 | Equity | CORP | United States | 59,379 | shares | $71.2M | 12.44% | 1 |
| Danaher Corp | 235851102 | Equity | CORP | United States | 57,611 | shares | $11M | 1.92% | 1 |
| Abbott Laboratories | 002824100 | Equity | CORP | United States | 119,561 | shares | $10.8M | 1.89% | 1 |
| Elevance Health Inc | 036752103 | Equity | CORP | United States | 27,515 | shares | $10.6M | 1.86% | 1 |
| Pfizer Inc | 717081103 | Equity | CORP | United States | 354,263 | shares | $8.5M | 1.49% | 1 |
| Argenx SE | 04016X101 | Equity | CORP | Netherlands | 8,058 | shares | $7.5M | 1.31% | 1 |
| Boston Scientific Corp | 101137107 | Equity | CORP | United States | 173,789 | shares | $7.4M | 1.30% | 1 |
| Biogen Inc | 09062X103 | Equity | CORP | United States | 31,869 | shares | $6.9M | 1.20% | 1 |
| Teva Pharmaceutical Industries Ltd | 881624209 | Equity | CORP | Israel | 195,347 | shares | $6.6M | 1.16% | 1 |
| Intuitive Surgical Inc | 46120E602 | Equity | CORP | United States | 16,457 | shares | $6.5M | 1.14% | 1 |
| Stryker Corp | 863667101 | Equity | CORP | United States | 19,938 | shares | $6.3M | 1.10% | 1 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 32,101 | shares | $6M | 1.05% | 1 |
| Moderna Inc | 60770K107 | Equity | CORP | United States | 81,325 | shares | $5.7M | 0.99% | 1 |
| Waters Corp | 941848103 | Equity | CORP | United States | 15,073 | shares | $5.7M | 0.99% | 1 |
| Cytokinetics Inc | 23282W605 | Equity | CORP | United States | 59,440 | shares | $5.1M | 0.88% | 1 |
| Regeneron Pharmaceuticals Inc | 75886F107 | Equity | CORP | United States | 7,712 | shares | $4.8M | 0.84% | 1 |
| Bristol-Myers Squibb Co | 110122108 | Equity | CORP | United States | 81,467 | shares | $4.7M | 0.82% | 1 |
| CVS Health Corp | 126650100 | Equity | CORP | United States | 41,701 | shares | $4.3M | 0.75% | 1 |
| Humana Inc | 444859102 | Equity | CORP | United States | 10,819 | shares | $4.3M | 0.75% | 1 |
| AstraZeneca PLC | GB0009895292 | Equity | CORP | United Kingdom | 22,678 | shares | $4.2M | 0.74% | 2 |
| Cogent Biosciences Inc | 19240Q201 | Equity | CORP | United States | 103,620 | shares | $4M | 0.70% | 1 |
| HCA Healthcare Inc | 40412C101 | Equity | CORP | United States | 10,127 | shares | $3.9M | 0.69% | 1 |
| Incyte Corp | 45337C102 | Equity | CORP | United States | 34,568 | shares | $3.9M | 0.68% | 1 |
| Dexcom Inc | 252131107 | Equity | CORP | United States | 57,910 | shares | $3.9M | 0.68% | 1 |
| Galderma Group AG | CH1335392721 | Equity | CORP | Switzerland | 16,599 | shares | $3.8M | 0.66% | 2 |
| Penumbra Inc | 70975L107 | Equity | CORP | United States | 11,606 | shares | $3.7M | 0.64% | 1 |
| Protagonist Therapeutics Inc | 74366E102 | Equity | CORP | United States | 29,705 | shares | $3.6M | 0.64% | 1 |
| Nuvalent Inc | 670703107 | Equity | CORP | United States | 28,618 | shares | $3.5M | 0.62% | 1 |
| Novartis AG | 66987V109 | Equity | CORP | Switzerland | 21,810 | shares | $3.4M | 0.60% | 1 |
| Insmed Inc | 457669307 | Equity | CORP | United States | 30,918 | shares | $3.3M | 0.58% | 1 |
| Agilent Technologies Inc | 00846U101 | Equity | CORP | United States | 23,884 | shares | $3.2M | 0.55% | 1 |
| Apogee Therapeutics Inc | 03770N101 | Equity | CORP | United States | 23,470 | shares | $3.1M | 0.54% | 1 |
| IDEXX Laboratories Inc | 45168D104 | Equity | CORP | United States | 5,896 | shares | $3.1M | 0.54% | 1 |
| Rhythm Pharmaceuticals Inc | 76243J105 | Equity | CORP | United States | 27,009 | shares | $3M | 0.52% | 1 |
| United Therapeutics Corp | 91307C102 | Equity | CORP | United States | 4,903 | shares | $2.7M | 0.46% | 1 |
| Illumina Inc | 452327109 | Equity | CORP | United States | 14,875 | shares | $2.6M | 0.46% | 1 |
| Alnylam Pharmaceuticals Inc | 02043Q107 | Equity | CORP | United States | 8,378 | shares | $2.5M | 0.44% | 1 |
| IQVIA Holdings Inc | 46266C105 | Equity | CORP | United States | 12,502 | shares | $2.4M | 0.42% | 1 |
| Oruka Therapeutics Inc | 687604108 | Equity | CORP | United States | 23,783 | shares | $2.3M | 0.40% | 1 |
| Bruker Corp | 116794108 | Equity | CORP | United States | 36,061 | shares | $2.2M | 0.38% | 1 |
| Axsome Therapeutics Inc | 05464T104 | Equity | CORP | United States | 8,010 | shares | $2M | 0.34% | 1 |
| Roivant Sciences Ltd | BMG762791017 | Equity | CORP | Bermuda | 55,068 | shares | $1.9M | 0.34% | 1 |
| Medline Inc | 58507V107 | Equity | CORP | United States | 47,171 | shares | $1.9M | 0.32% | 1 |
| McKesson Corp | 58155Q103 | Equity | CORP | United States | 2,451 | shares | $1.9M | 0.32% | 1 |
| Neurocrine Biosciences Inc | 64125C109 | Equity | CORP | United States | 10,232 | shares | $1.7M | 0.30% | 1 |
| BioMarin Pharmaceutical Inc | 09061G101 | Equity | CORP | United States | 29,577 | shares | $1.7M | 0.30% | 1 |
| Dianthus Therapeutics Inc | 252828108 | Equity | CORP | United States | 16,460 | shares | $1.6M | 0.28% | 1 |
| Arcus Biosciences Inc | 03969F109 | Equity | CORP | United States | 51,616 | shares | $1.6M | 0.28% | 1 |
| Quest Diagnostics Inc | 74834L100 | Equity | CORP | United States | 7,463 | shares | $1.6M | 0.28% | 1 |
| MBX Biosciences Inc | 55287L101 | Equity | CORP | United States | 28,457 | shares | $1.6M | 0.27% | 1 |
| LB Pharmaceuticals Inc | 50180M108 | Equity | CORP | United States | 48,308 | shares | $1.6M | 0.27% | 1 |
| UCB SA | BE0003739530 | Equity | CORP | Belgium | 4,719 | shares | $1.4M | 0.25% | 2 |
| Stoke Therapeutics Inc | 86150R107 | Equity | CORP | United States | 41,095 | shares | $1.3M | 0.23% | 1 |
| Madrigal Pharmaceuticals Inc | 558868105 | Equity | CORP | United States | 2,494 | shares | $1.3M | 0.23% | 1 |
| Bio-Techne Corp | 09073M104 | Equity | CORP | United States | 17,090 | shares | $1.2M | 0.21% | 1 |
| Ionis Pharmaceuticals Inc | 462222100 | Equity | CORP | United States | 14,983 | shares | $1.2M | 0.21% | 1 |
| Cencora Inc | 03073E105 | Equity | CORP | United States | 4,124 | shares | $1.2M | 0.20% | 1 |
| Erasca Inc | 29479A108 | Equity | CORP | United States | 62,282 | shares | $1.1M | 0.20% | 1 |
| Charles River Laboratories International Inc | 159864107 | Equity | CORP | United States | 4,936 | shares | $1.1M | 0.20% | 1 |
| Natera Inc | 632307104 | Equity | CORP | United States | 4,111 | shares | $1.1M | 0.19% | 1 |
| Scholar Rock Holding Corp | 80706P103 | Equity | CORP | United States | 19,764 | shares | $1.1M | 0.19% | 1 |
| Exelixis Inc | 30161Q104 | Equity | CORP | United States | 19,863 | shares | $1.1M | 0.19% | 1 |
| Glaukos Corp | 377322102 | Equity | CORP | United States | 7,625 | shares | $1.1M | 0.19% | 1 |
| West Pharmaceutical Services Inc | 955306105 | Equity | CORP | United States | 2,911 | shares | $1M | 0.18% | 1 |
| Elanco Animal Health Inc | 28414H103 | Equity | CORP | United States | 41,073 | shares | $1M | 0.18% | 1 |
| Intellia Therapeutics Inc | 45826J105 | Equity | CORP | United States | 59,711 | shares | $1M | 0.18% | 1 |
| Daiichi Sankyo Co Ltd | JP3475350009 | Equity | CORP | Japan | 60,800 | shares | $978K | 0.17% | 2 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 41,127 | shares | $906K | 0.16% | 1 |
| Agios Pharmaceuticals Inc | 00847X104 | Equity | CORP | United States | 24,400 | shares | $905K | 0.16% | 1 |
| Viridian Therapeutics Inc | 92790C104 | Equity | CORP | United States | 45,005 | shares | $827K | 0.14% | 1 |
| Eikon Therapeutics Inc | 282564103 | Equity | CORP | United States | 63,218 | shares | $825K | 0.14% | 1 |
| KAILERA THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 36,000 | shares | $793K | 0.14% | 2 |
| Vaxcyte Inc | 92243G108 | Equity | CORP | United States | 13,092 | shares | $761K | 0.13% | 1 |
| Novocure Ltd | JE00BYSS4X48 | Equity | CORP | Jersey | 49,947 | shares | $757K | 0.13% | 1 |
| ADARX PHARMACEUTICALS INCrestricted | — | Equity | CORP | United States | 52,885 | shares | $749K | 0.13% | 3 |
| Aktis Oncology Inc | 01021M104 | Equity | CORP | United States | 23,229 | shares | $749K | 0.13% | 1 |
| Alumis Inc | 022307102 | Equity | CORP | United States | 25,795 | shares | $726K | 0.13% | 1 |
| Mettler-Toledo International Inc | 592688105 | Equity | CORP | United States | 548 | shares | $700K | 0.12% | 1 |
| Palvella Therapeutics Inc | 697947109 | Equity | CORP | United States | 4,480 | shares | $685K | 0.12% | 1 |
| Monte Rosa Therapeutics Inc | 61225M102 | Equity | CORP | United States | 27,954 | shares | $676K | 0.12% | 1 |
| KARTOS THERAPEUTICS INCrestricted | — | Short-term inv. | CORP | United States | 152,163 | shares | $664K | 0.12% | 3 |
| BlackRock Funds III | 066922519 | Short-term inv. | RF | United States | 653,766 | shares | $654K | 0.11% | 1 |
| Enanta Pharmaceuticals Inc | 29251M106 | Equity | CORP | United States | 42,512 | shares | $620K | 0.11% | 1 |
| Tango Therapeutics Inc | 87583X109 | Equity | CORP | United States | 19,426 | shares | $607K | 0.11% | 1 |
| Bright Minds Biosciences Inc | 10919W405 | Equity | CORP | Canada | 8,368 | shares | $587K | 0.10% | 1 |
| Bridgebio Pharma Inc | 10806X102 | Equity | CORP | United States | 7,857 | shares | $585K | 0.10% | 1 |
| RadNet Inc | 750491102 | Equity | CORP | United States | 9,485 | shares | $585K | 0.10% | 1 |
| Denali Therapeutics Inc | 24823R105 | Equity | CORP | United States | 22,218 | shares | $571K | 0.10% | 1 |
| Relay Therapeutics Inc | 75943R102 | Equity | CORP | United States | 30,472 | shares | $570K | 0.10% | 1 |
| Angitia Biopharmaceuticals Limitedrestricted | — | Short-term inv. | CORP | United States | 57,448 | shares | $568K | 0.10% | 3 |
| Kymera Therapeutics Inc | 501575104 | Equity | CORP | United States | 4,712 | shares | $540K | 0.09% | 1 |
| Immunome Inc | 45257U108 | Equity | CORP | United States | 25,340 | shares | $537K | 0.09% | 1 |
| Dyne Therapeutics Inc | 26818M108 | Equity | CORP | United States | 23,908 | shares | $531K | 0.09% | 1 |
| Immunocore Holdings PLC | 45258D105 | Equity | CORP | United Kingdom | 16,565 | shares | $526K | 0.09% | 1 |
| Beam Therapeutics Inc | 07373V105 | Equity | CORP | United States | 14,611 | shares | $501K | 0.09% | 1 |
| Avalo Therapeutics Inc | 05338F306 | Equity | CORP | United States | 27,026 | shares | $499K | 0.09% | 1 |
| Maze Therapeutics Inc | 578784100 | Equity | CORP | United States | 15,965 | shares | $476K | 0.08% | 1 |
| BridgeBio Oncology Therapeutics Inc | 107924102 | Equity | CORP | United States | 60,030 | shares | $457K | 0.08% | 1 |
| Biohaven Ltd | VGG1110E1079 | Equity | CORP | British Virgin Islands | 30,469 | shares | $453K | 0.08% | 1 |
| Kodiak Sciences Inc | 50015M109 | Equity | CORP | United States | 11,389 | shares | $444K | 0.08% | 1 |
| GENESIS THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 57,170 | shares | $422K | 0.07% | 3 |
| Bicara Therapeutics Inc | 055477103 | Equity | CORP | United States | 14,144 | shares | $420K | 0.07% | 1 |
| Sagimet Biosciences Inc | 786700104 | Equity | CORP | United States | 52,449 | shares | $405K | 0.07% | 1 |
| NUCLEIX LTDrestricted | — | Preferred | CORP | United States | 367,595 | shares | $389K | 0.07% | 3 |
| Ultragenyx Pharmaceutical Inc | 90400D108 | Equity | CORP | United States | 11,623 | shares | $388K | 0.07% | 1 |
| Alcon AG | CH0432492467 | Equity | CORP | Switzerland | 5,751 | shares | $386K | 0.07% | 1 |
| Summit Therapeutics Inc | 86627T108 | Equity | CORP | United States | 25,126 | shares | $366K | 0.06% | 1 |
| PTC Therapeutics Inc | 69366J200 | Equity | CORP | United States | 4,329 | shares | $353K | 0.06% | 1 |
| LARONDE INCrestricted | — | Equity | CORP | United States | 21,100 | shares | $352K | 0.06% | 3 |
| Definium Therapeutics Inc | 24477V105 | Equity | CORP | Canada | 7,322 | shares | $344K | 0.06% | 1 |
| BioNTech SE | 09075V102 | Equity | CORP | Germany | 3,695 | shares | $344K | 0.06% | 1 |
| Zealand Pharma A/S | DK0060257814 | Equity | CORP | Denmark | 7,187 | shares | $319K | 0.06% | 2 |
| MoonLake Immunotherapeutics | 61559X104 | Equity | CORP | Cayman Islands | 14,299 | shares | $278K | 0.05% | 1 |
| EyePoint Inc | 30233G209 | Equity | CORP | United States | 16,320 | shares | $233K | 0.04% | 1 |
| Ocular Therapeutix Inc | 67576A100 | Equity | CORP | United States | 22,645 | shares | $222K | 0.04% | 1 |
| REGENXBIO Inc | 75901B107 | Equity | CORP | United States | 18,415 | shares | $221K | 0.04% | 1 |
| Allogene Therapeutics Inc | 019770106 | Equity | CORP | United States | 104,283 | shares | $217K | 0.04% | 1 |
| Upstream Bio Inc | 91678A107 | Equity | CORP | United States | 30,052 | shares | $208K | 0.04% | 1 |
| INSITRO INCrestricted | — | Equity | CORP | United States | 30,616 | shares | $205K | 0.04% | 3 |
| Vor BioPharma Inc | 929033207 | Equity | CORP | United States | 10,020 | shares | $184K | 0.03% | 1 |
| WaVe Life Sciences Ltd | SG9999014716 | Equity | CORP | Singapore | 30,090 | shares | $175K | 0.03% | 1 |
| Quanta Dialysis Technologies Ltdrestricted | — | Equity | CORP | United Kingdom | 4,243,029 | shares | $174K | 0.03% | 3 |
| MapLight Therapeutics Inc | 56565P103 | Equity | CORP | United States | 4,464 | shares | $160K | 0.03% | 1 |
| 4D Molecular Therapeutics Inc | 35104E100 | Equity | CORP | United States | 11,491 | shares | $153K | 0.03% | 1 |
| Corvus Pharmaceuticals Inc | 221015100 | Equity | CORP | United States | 9,689 | shares | $145K | 0.03% | 1 |
| BRIDGEBIO ONCOLOGY THERAPEUTICS INCrestricted | — | Equity | CORP | United States | 15,582 | shares | $119K | 0.02% | 2 |
| Syndax Pharmaceuticals Inc | 87164F105 | Equity | CORP | United States | 5,165 | shares | $113K | 0.02% | 1 |
| Annexon Inc | 03589W102 | Equity | CORP | United States | 16,787 | shares | $95.9K | 0.02% | 1 |
| Orchestra BioMed Holdings Inc | 68572M106 | Equity | CORP | United States | 17,635 | shares | $76.1K | 0.01% | 1 |
| GOLDFINCH BIO INCrestricted | — | Equity | CORP | United States | 168,216 | shares | $50.5K | 0.01% | 3 |
| EXO IMAGING INCrestricted | — | Equity | CORP | United States | 48,514 | shares | $35.5K | 0.01% | 3 |
| CELLARITY INCrestricted | — | Equity | CORP | United States | 44,167 | shares | $25.6K | 0.00% | 3 |
| AFFINIVAX INCrestricted | — | Equity | CORP | United States | 6,331 | shares | $23.2K | 0.00% | 3 |
| CONTRA ABIOMED INC | 003CVR016 | OTHER | CORP | United States | 14,359 | shares | $21.8K | 0.00% | 3 |
| CONTRA BLUEPRINT MEDIC | 096CVR048 | OTHER | CORP | United States | 15,552 | shares | $15.4K | 0.00% | 3 |
| CONTRA MIRATI THERAPEU | 604CVR027 | OTHER | CORP | United States | 15,747 | shares | $12.4K | 0.00% | 3 |
| Gossamer Bio Inc | 38341P102 | Equity | CORP | United States | 31,955 | shares | $5.3K | 0.00% | 1 |
| CONTRA ARCELLX INC | 039CVR014 | OTHER | CORP | United States | 8,208 | shares | $575 | 0.00% | 2 |
| SWIFT HEALTH SYSTEMS INCrestricted | — | Equity | CORP | United States | 93 | shares | $206 | 0.00% | 3 |
| CONTRA HOLOGIC INCORPO | 436CVR021 | OTHER | CORP | United States | 12,193 | shares | $122 | 0.00% | 2 |
| CONTRA FREQUENCY THERA | 358CVR025 | OTHER | CORP | United States | 28,060 | shares | $0 | 0.00% | 3 |
| GOLDFINCH EQUITY WARRANTS | — | Equity deriv. | OTHER | United States | 21,784 | shares | $0 | 0.00% | 3 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 25, 2026 | 152 | 100.0% | $573M | full |
| Mar 31, 2026 | May 28, 2026 | 155 | 100.0% | $535M | full |
| Dec 31, 2025 | Feb 24, 2026 | 155 | 100.0% | $570M | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for BlackRock Health Sciences Trust. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.